WilmerHale advised the underwriters in the public offering of Disc Medicine, Inc. (Disc) (Nasdaq: IRON) which included the issuance and sale by Disc of 2,619,049 shares of common stock and pre-funded warrants to purchase 59,523 shares of common stock and the sale by one of Disc’s stockholders, AI DMI LLC, of 744,047 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 446,428 additional shares from the selling stockholder. Disc is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. Disc received approximately $225.0 million in gross proceeds, and the selling stockholder received approximately $62.5 million in gross proceeds, in each case, excluding underwriting discounts, commissions and other offering-related expenses.

The WilmerHale team was led by Partner Lisa Firenze and included Counsels Andrea Sorrentino and Katharine Patterson, along with Associates Connor McRory and Amy O’Connell.